<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="233">
  <stage>Registered</stage>
  <submitdate>5/07/2000</submitdate>
  <approvaldate>5/07/2000</approvaldate>
  <nctid>NCT00006004</nctid>
  <trial_identification>
    <studytitle>Comparison of Two Combination Chemotherapy Regimens in Treating Non-small Cell Lung Cancer</studytitle>
    <scientifictitle>A Randomized Phase II Trial of Paclitaxel-Carboplatin or Gemicitabine-Cisplatin in ECOG Performance Status 2 Non-Small Cell Lung Cancer Patients</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>E-1599</secondaryid>
    <secondaryid>CDR0000068012</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Lung Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Mesothelioma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Small cell</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - carboplatin
Treatment: drugs - cisplatin
Treatment: drugs - gemcitabine hydrochloride
Treatment: drugs - paclitaxel

Treatment: drugs: carboplatin


Treatment: drugs: cisplatin


Treatment: drugs: gemcitabine hydrochloride


Treatment: drugs: paclitaxel


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes />
  <eligibility>
    <inclusivecriteria>DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed non-small cell lung carcinoma of any of the
             following subtypes:

               -  Squamous cell

               -  Adenocarcinoma

               -  Large cell anaplastic

               -  Bronchioalveolar

               -  Non-small cell carcinoma not otherwise specified

          -  No small cell anaplastic elements allowed

          -  Must have:

               -  Recurrent disease after prior radiotherapy or surgery OR

               -  Stage IV disease with distant metastases OR

               -  Stage IIIB disease presenting with pleural or pericardial effusion on CT or chest
                  x-ray or pleural implants documented pathologically or on CT or chest x-ray

          -  Bidimensionally measurable or evaluable disease

          -  Brain metastases allowed provided clinically stable after treatment with surgery
             and/or radiotherapy

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  ECOG 2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Absolute neutrophil count at least 1,500/mm3

          -  Platelet count at least 100,000/mm3

        Hepatic:

          -  Bilirubin no greater than 1.5 mg/dL

          -  SGOT no greater than 5 times upper limit of normal

        Renal:

          -  Creatinine no greater than 1.5 mg/dL OR

          -  Creatinine clearance at least 60 mL/min

        Cardiovascular:

          -  No uncontrolled high blood pressure, unstable angina, or congestive heart failure

          -  No myocardial infarction within the past 6 months

          -  No serious ventricular arrhythmias requiring medication

        Other:

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No other active malignancies requiring ongoing treatment

          -  No uncontrolled serious active infections

          -  No suspected hypersensitivity to agents that utilize Cremophor

          -  No evidence of neuropathy grade 2 or greater by history or physical examination

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No prior chemotherapy for non-small cell lung cancer

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  See Disease Characteristics

          -  No prior radiotherapy to only site of measurable or evaluable disease unless
             subsequent progression documented by physical exam, radiograph, or pathology

          -  Recovered from prior radiotherapy

          -  No concurrent radiotherapy except for whole brain radiation for developing brain
             metastases

        Surgery:

          -  See Disease Characteristics</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2000</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Westmead Hospital - Westmead</hospital>
    <postcode>2145 - Westmead</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Peru</country>
      <state>Lima</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>San Juan</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Eastern Cooperative Oncology Group</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>National Cancer Institute (NCI)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining more than one drug may kill more tumor cells. It is not
      yet known which combination chemotherapy regimen is more effective for treating non-small
      cell lung cancer.

      PURPOSE: Randomized phase II trial to compare the effectiveness of two combination
      chemotherapy regimens in treating patients who have non-small cell lung cancer.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00006004</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Corey J. Langer, MD</name>
      <address>Fox Chase Cancer Center</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>